AN2 Therapeutics, Inc.
ANTX
$5.62
-$0.36-6.02%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -16.40% | -6.80% | -5.16% | -4.33% | -3.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.82% | -22.33% | -30.14% | -42.25% | -45.02% |
| Operating Income | 0.82% | 22.33% | 30.14% | 42.25% | 45.02% |
| Income Before Tax | 2.95% | 23.81% | 31.46% | 44.01% | 42.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 2.95% | 23.81% | 31.46% | 44.01% | 42.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.95% | 23.81% | 31.46% | 44.01% | 42.19% |
| EBIT | 0.82% | 22.33% | 30.14% | 42.25% | 45.02% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 13.97% | 27.21% | 32.36% | 44.59% | 44.86% |
| Normalized Basic EPS | 8.49% | 23.43% | 29.26% | 42.44% | 48.16% |
| EPS Diluted | 13.97% | 27.21% | 32.36% | 44.59% | 44.86% |
| Normalized Diluted EPS | 8.49% | 23.43% | 29.26% | 42.44% | 48.16% |
| Average Basic Shares Outstanding | 16.26% | 4.40% | 1.30% | 1.02% | 4.33% |
| Average Diluted Shares Outstanding | 16.26% | 4.40% | 1.30% | 1.02% | 4.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |